Introduction: As new vaccines become available, countries must assess the relevance to introduce them into their vaccination schedules. Malawi has recently introduced several new vaccines and plans to introduce more. ...Introduction: As new vaccines become available, countries must assess the relevance to introduce them into their vaccination schedules. Malawi has recently introduced several new vaccines and plans to introduce more. This study was conducted to identify key factors that need to be considered when deciding to introduce a new vaccine and current challenges faced by low and middle income countries using Malawi as an example. Methodology: The study employed a desk review approach, examining published literature from various sources such as PubMed, Medline, and Google Scholar. Policy documents from organizations like the World Health Organization, GAVI the Alliance, and the Ministry of Health for Malawi were also included. A total of 99 articles and documents on new vaccine introduction, challenges of immunization, policy documents in immunization and health systems strengthening were included. The review focused on addressing five key areas critical to new vaccine introduction namely: the need for a vaccine, availability of the vaccine, safety and effectiveness of the vaccine, demand for the vaccine, and the prudent use of public or private funds. Results: Malawi considered the burden of cervical cancer and the significance of malaria in the country when introducing the HPV and malaria vaccines. The country opted for vaccines that can be handled by the cold chain capacity and available human resources. Despite that malaria vaccine and Typhoid Conjugate Vaccine trials were done in country, there are limited vaccine safety and efficacy trials conducted in Malawi, leading to a reliance on WHO-prequalified vaccines. Demand for newly introduced vaccines varied, with high demand for Oral Cholera Vaccine during a cholera outbreak, while demand for COVID-19 vaccines decreased over time. Although cost-effectiveness studies were limited in the country, 2 studies indicated that Typhoid Conjugate Vaccine and malaria vaccine would be cost effective. All these have been implemented despite having challenges like lack of accurate surveillance data, inadequate cold chain capacity, limited safety and efficacy vaccine clinical trials, political influence, and limited funding. Conclusion: Despite several challenges Malawi set a good example of the careful considerations required before introducing a new vaccine. The process involves data review, priority setting, precise planning, and consultation with stakeholders. Low-income countries should invest in vaccine safety, efficacy, and cost-effectiveness trials.展开更多
Objective:To assess levels of HBs Ab amongst infants who received hepatitis B vaccine in the Expanded Program on Immunization in Vietnam.Methods:A cross-sectional study was carried out at 16 community health centers f...Objective:To assess levels of HBs Ab amongst infants who received hepatitis B vaccine in the Expanded Program on Immunization in Vietnam.Methods:A cross-sectional study was carried out at 16 community health centers from February 2016 to July 2017.Eligible infants were tested for HBs Ab and HBs Ag.Structured questionnaires were used to collect relevant information about the demographics of the parents/caregivers and their infants after physical examination.Results:A total of 199 eligible infants were selected with a mean age of(17.3±4.5)months.Protective antibody levels with HBs Ab≥10 m IU/m L were detected in 68.3%of infants.Of these,antibody levels from 10 to 99 m IU/m L were 48.5%of those tested and antibody levels≥100 ml U/m L were recorded as 51.5%.No cases were recorded of being infected with hepatitis B virus.The rate of positive HBs Ab level in those who were not wasting and≥18 months old was less than that among those who were<18 months old(OR 0.49,95%CI:0.26-0.92,P<0.05)while the infants with wasting and<18 months were less likely to be positive HBs Ab than those who were not wasting and of the same age group(OR 0.15,95%CI:0.04-0.55,P<0.05).Conclusions:Seroprotection against hepatitis B virus was low in the infants tested(at 68.3%),which suggests that the hepatitis B vaccine should be administered with one additional dose for infants between 12 and 24 months of age,particularly those with wasting.展开更多
目的了解孕妇对未来子女非免疫规划疫苗(expanded program on immunization,EPI)的接种意愿及其影响因素,为提高儿童非EPI接种率提供参考。方法采用便利抽样的方法,选取山西省妇幼保健院438名产检孕妇为研究对象进行问卷调查。利用独立...目的了解孕妇对未来子女非免疫规划疫苗(expanded program on immunization,EPI)的接种意愿及其影响因素,为提高儿童非EPI接种率提供参考。方法采用便利抽样的方法,选取山西省妇幼保健院438名产检孕妇为研究对象进行问卷调查。利用独立样本t检验、方差分析和多重线性回归模型分析个人社会经济因素、疫苗倾向和疫苗信息获取渠道对孕妇为未来子女接种非EPI意愿的影响,并基于计划行为理论构建结构方程模型分析孕妇对子女非EPI接种的态度、主观规范、知觉行为控制对接种意愿的影响。结果98.4%调查对象愿意为子女接种非EPI。与倾向于接种进口疫苗的群体相比,有接种国产疫苗倾向的群体(β=0.119)为子女接种非EPI的意愿更强,有接触媒体宣传较没有接触的群体子女非EPI接种意愿更强(β=0.099),有接触社区医院和疾病预防控制中心的宣传册和活动讲座的群体较没有接触的群体子女非EPI接种意愿更强(β=0.119)。结构方程模型结果显示影响接种意愿强度的因素从大到小依次为知觉行为控制、行为态度、主观规范(路径系数分别为0.73,0.13,0.12)。结论孕妇对未来子女非EPI的接种意愿水平较高。加强非EPI接种宣传教育,改变孕妇对非EPI的知觉行为控制和态度,能够帮助提高儿童非EPI接种率。展开更多
文摘Introduction: As new vaccines become available, countries must assess the relevance to introduce them into their vaccination schedules. Malawi has recently introduced several new vaccines and plans to introduce more. This study was conducted to identify key factors that need to be considered when deciding to introduce a new vaccine and current challenges faced by low and middle income countries using Malawi as an example. Methodology: The study employed a desk review approach, examining published literature from various sources such as PubMed, Medline, and Google Scholar. Policy documents from organizations like the World Health Organization, GAVI the Alliance, and the Ministry of Health for Malawi were also included. A total of 99 articles and documents on new vaccine introduction, challenges of immunization, policy documents in immunization and health systems strengthening were included. The review focused on addressing five key areas critical to new vaccine introduction namely: the need for a vaccine, availability of the vaccine, safety and effectiveness of the vaccine, demand for the vaccine, and the prudent use of public or private funds. Results: Malawi considered the burden of cervical cancer and the significance of malaria in the country when introducing the HPV and malaria vaccines. The country opted for vaccines that can be handled by the cold chain capacity and available human resources. Despite that malaria vaccine and Typhoid Conjugate Vaccine trials were done in country, there are limited vaccine safety and efficacy trials conducted in Malawi, leading to a reliance on WHO-prequalified vaccines. Demand for newly introduced vaccines varied, with high demand for Oral Cholera Vaccine during a cholera outbreak, while demand for COVID-19 vaccines decreased over time. Although cost-effectiveness studies were limited in the country, 2 studies indicated that Typhoid Conjugate Vaccine and malaria vaccine would be cost effective. All these have been implemented despite having challenges like lack of accurate surveillance data, inadequate cold chain capacity, limited safety and efficacy vaccine clinical trials, political influence, and limited funding. Conclusion: Despite several challenges Malawi set a good example of the careful considerations required before introducing a new vaccine. The process involves data review, priority setting, precise planning, and consultation with stakeholders. Low-income countries should invest in vaccine safety, efficacy, and cost-effectiveness trials.
文摘Objective:To assess levels of HBs Ab amongst infants who received hepatitis B vaccine in the Expanded Program on Immunization in Vietnam.Methods:A cross-sectional study was carried out at 16 community health centers from February 2016 to July 2017.Eligible infants were tested for HBs Ab and HBs Ag.Structured questionnaires were used to collect relevant information about the demographics of the parents/caregivers and their infants after physical examination.Results:A total of 199 eligible infants were selected with a mean age of(17.3±4.5)months.Protective antibody levels with HBs Ab≥10 m IU/m L were detected in 68.3%of infants.Of these,antibody levels from 10 to 99 m IU/m L were 48.5%of those tested and antibody levels≥100 ml U/m L were recorded as 51.5%.No cases were recorded of being infected with hepatitis B virus.The rate of positive HBs Ab level in those who were not wasting and≥18 months old was less than that among those who were<18 months old(OR 0.49,95%CI:0.26-0.92,P<0.05)while the infants with wasting and<18 months were less likely to be positive HBs Ab than those who were not wasting and of the same age group(OR 0.15,95%CI:0.04-0.55,P<0.05).Conclusions:Seroprotection against hepatitis B virus was low in the infants tested(at 68.3%),which suggests that the hepatitis B vaccine should be administered with one additional dose for infants between 12 and 24 months of age,particularly those with wasting.
文摘目的了解孕妇对未来子女非免疫规划疫苗(expanded program on immunization,EPI)的接种意愿及其影响因素,为提高儿童非EPI接种率提供参考。方法采用便利抽样的方法,选取山西省妇幼保健院438名产检孕妇为研究对象进行问卷调查。利用独立样本t检验、方差分析和多重线性回归模型分析个人社会经济因素、疫苗倾向和疫苗信息获取渠道对孕妇为未来子女接种非EPI意愿的影响,并基于计划行为理论构建结构方程模型分析孕妇对子女非EPI接种的态度、主观规范、知觉行为控制对接种意愿的影响。结果98.4%调查对象愿意为子女接种非EPI。与倾向于接种进口疫苗的群体相比,有接种国产疫苗倾向的群体(β=0.119)为子女接种非EPI的意愿更强,有接触媒体宣传较没有接触的群体子女非EPI接种意愿更强(β=0.099),有接触社区医院和疾病预防控制中心的宣传册和活动讲座的群体较没有接触的群体子女非EPI接种意愿更强(β=0.119)。结构方程模型结果显示影响接种意愿强度的因素从大到小依次为知觉行为控制、行为态度、主观规范(路径系数分别为0.73,0.13,0.12)。结论孕妇对未来子女非EPI的接种意愿水平较高。加强非EPI接种宣传教育,改变孕妇对非EPI的知觉行为控制和态度,能够帮助提高儿童非EPI接种率。
